

Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030

Market Report | 2025-10-30 | 317 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global veterinary biologics market is projected to reach USD 3.51 billion by 2030 from USD 2.72 billion in 2025, at a CAGR of 5.2% during the forecast period.

<https://mnmimg.marketsandmarkets.com/Images/veterinary-biologics-market-overview.webp>

The veterinary biologics market is experiencing significant growth, driven by an expanding companion animal population and rising pet ownership. Increasing concerns about chronic diseases have further boosted demand for veterinary treatments. Government and animal welfare organizations actively promote awareness campaigns, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. Additionally, the growing adoption of pet insurance and high expenditure on animal healthcare support market expansion by improving access to specialized veterinary services. However, the market faces challenges such as the rising cost of pet care, which can limit treatment adoption. Moreover, strict regulatory guidelines and lengthy drug approval processes further restrain market growth.

"The monoclonal antibodies segment has accounted for the largest market share in the veterinary biologics market." Monoclonal antibodies are projected to experience rapid growth in the veterinary biologics market, driven by their targeted action, high effectiveness, and increasing adoption in livestock health management. These biologics are increasingly used to prevent and treat specific diseases by precisely targeting pathogens or toxins, providing a more selective and effective alternative to

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

traditional therapies like antibiotics. In livestock applications, monoclonal antibodies are especially valuable for conditions that require swift immune support, resulting in decreased morbidity and higher productivity. Their use aligns with the global shift toward sustainable animal farming practices and the reduction of antimicrobial resistance (AMR), making them a preferred choice for advanced biologic treatments.

"The dermatology segment accounted for the largest market share in 2024 in the veterinary biologics market."

The dermatology segment is expected to dominate the veterinary biologics market because of the high prevalence of skin disorders like atopic dermatitis, mange, and flea- or tick-borne skin infections in companion animals. Increasing pet ownership and greater awareness of animal health have boosted demand for advanced dermatological treatments. Biologics, such as monoclonal antibodies, are becoming more popular as effective, targeted therapies with fewer side effects compared to traditional drugs. More approvals of dermatology-focused veterinary biologics, including those targeting chronic skin allergies, further strengthen this segment. Additionally, dermatological issues are among the most common reasons for veterinary visits, ensuring steady demand. Growth in companion animal insurance coverage is also supporting the adoption of high-cost biologics. Overall, these factors position dermatology as the leading segment in the veterinary biologics market.

"North America has accounted for the largest market share in 2024."

North America held the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in research and development for innovative monoclonal antibody therapies. Rising awareness about pet health, along with increasing spending on veterinary care, drives market growth. Additionally, the growing demand for premium pet care products further contributes to North America's dominance in the global veterinary monoclonal antibody industry.

A breakdown of the primary participants referred to for this report is provided below:

-□By Company Type: Tier 1-75%, Tier 2-15%, and Tier 3- 10%

-□By Designation: C-level-30%, Director-level-23%, and Other Designations-47%

-□By Region: North America-35%, Europe-20%, Asia Pacific-25%, Latin America-13%, and Middle East & Africa-7%

The major players operating in the veterinary biologics market are Zoetis (US), Elanco (US), and Merck & Co., Inc. (US).

Research Coverage

This report studies the veterinary biologics market based on animal type, route of administration, product, application, end user, and region. The report also examines factors such as drivers, restraints, opportunities, and challenges that affect market growth. It analyzes the opportunities and challenges within the market and provides details about the competitive landscape for market leaders. Additionally, the report analyzes micro markets in terms of their individual growth trends and forecasts the revenue of market segments across five main regions and their respective countries.

Reasons to Buy the Report

The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.

This report provides insights into the following points:

-□Analysis of key drivers (Surge in companion animal population and pet ownership. Increasing incidence of infectious zoonotic diseases, Innovations in monoclonal antibodies targeting infectious diseases, Supportive initiatives by government agencies and animal health organization, Growing demand for animal-derived food products), restraints (High cost of veterinary diagnostic tests, Regulatory hurdles and long approval timelines), opportunities (evolving landscape of strategic collaborations and partnerships, untapped growth potential in emerging markets, challenges (Limited Awareness and Shortage of Trained Veterinarians in Low-Income Countries).

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary biologics market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of biologic treatments across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary biologics market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary biologics market.

Table of Contents:

- 1□INTRODUCTION□29
- 1.1□STUDY OBJECTIVES□29
- 1.2□MARKET DEFINITION□29
- 1.3□STUDY SCOPE□30
- 1.3.1□MARKET SEGMENTATION & REGIONAL SCOPE□30
- 1.3.2□INCLUSIONS & EXCLUSIONS□31
- 1.3.3□YEARS CONSIDERED□32
- 1.3.4□CURRENCY CONSIDERED□32
- 1.4□STAKEHOLDERS□32
- 2□RESEARCH METHODOLOGY□33
- 2.1□RESEARCH DATA□33
- 2.1.1□SECONDARY DATA□34
- 2.1.1.1□Key secondary sources□34
- 2.1.1.2□Key data from secondary sources□35
- 2.1.2□PRIMARY DATA□35
- 2.1.2.1□Primary sources□36
- 2.1.2.2□Key objectives of primary research□36
- 2.1.2.3□Key industry insights□37
- 2.1.2.4□Breakdown of primaries□37
- 2.2□MARKET SIZE ESTIMATION□39
- 2.2.1□REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)□39
- 2.2.2□EPIDEMIOLOGY-BASED APPROACH□40
- 2.2.3□COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS□41
- 2.2.4□TOP-DOWN APPROACH□41
- 2.2.5□BOTTOM-UP APPROACH□42
- 2.3□MARKET GROWTH RATE PROJECTION□42
- 2.4□DATA TRIANGULATION□44
- 2.5□STUDY ASSUMPTIONS□45
- 2.6□RESEARCH LIMITATIONS□45
- 2.7□RISK ANALYSIS□46
- 3□EXECUTIVE SUMMARY□47
- ?
- 4□PREMIUM INSIGHTS□52
- 4.1□VETERINARY BIOLOGICS MARKET OVERVIEW□52
- 4.2□NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE AND COUNTRY□53
- 4.3□VETERINARY BIOLOGICS MARKET SHARE, BY PRODUCT TYPE, 2025 VS. 2030□53
- 4.4□VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2025 VS. 2030 (USD MILLION)□54

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.5	VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)	54
4.6	VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)	55
4.7	VETERINARY BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	56
5	MARKET OVERVIEW	57
5.1	INTRODUCTION	57
5.2	MARKET DYNAMICS	57
5.2.1	DRIVERS	58
5.2.1.1	Surge in companion animal population and pet ownership	58
5.2.1.2	Increasing incidence of infectious zoonotic diseases	59
5.2.1.3	Innovations in monoclonal antibodies targeting infectious diseases	60
5.2.1.4	Supportive initiatives by government agencies and animal health organizations	61
5.2.1.5	Rising demand for animal-derived food products	61
5.2.2	RESTRAINTS	63
5.2.2.1	High cost of veterinary diagnostic tests	63
5.2.2.2	Regulatory hurdles and long approval timelines	64
5.2.2.3	Rising pet care costs	64
5.2.3	OPPORTUNITIES	65
5.2.3.1	Evolving landscape of strategic collaborations and acquisitions	65
5.2.3.2	Untapped growth potential in emerging economies	66
5.2.4	CHALLENGES	66
5.2.4.1	Limited awareness and shortage of trained veterinarians in low-income countries	66
5.2.4.2	Stringent regulatory requirements for licensing veterinary biologics	67
5.3	TECHNOLOGY ANALYSIS	67
5.3.1	KEY TECHNOLOGIES	67
5.3.1.1	Hybridoma technology	67
5.3.1.2	Biosensor-based diagnostic systems	68
5.3.2	COMPLEMENTARY TECHNOLOGIES	68
5.3.2.1	Long-acting injectables	68
5.3.2.2	Next-generation sequencing	68
5.3.3	ADJACENT TECHNOLOGIES	69
5.3.3.1	Wearable biosensors & remote monitoring devices	69
5.4	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	69
?		
5.5	VALUE CHAIN ANALYSIS	70
5.6	TRADE ANALYSIS	71
5.6.1	IMPORT DATA FOR HS CODE 300214, 2021-2024	72
5.6.2	EXPORT DATA FOR HS CODE 300214, 2021-2024	72
5.7	PORTER'S FIVE FORCES ANALYSIS	73
5.7.1	THREAT OF NEW ENTRANTS	74
5.7.2	THREAT OF SUBSTITUTES	74
5.7.3	BARGAINING POWER OF SUPPLIERS	74
5.7.4	BARGAINING POWER OF BUYERS	74
5.7.5	INTENSITY OF COMPETITIVE RIVALRY	75
5.8	KEY STAKEHOLDERS & BUYING CRITERIA	75
5.8.1	KEY STAKEHOLDERS IN BUYING PROCESS	75
5.8.2	KEY BUYING CRITERIA	76
5.9	REGULATORY ANALYSIS	77

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.9.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	77
5.9.2	REGULATORY FRAMEWORK	80
5.9.2.1	North America	80
5.9.2.2	Europe	81
5.9.2.3	Asia Pacific	81
5.9.2.4	Latin America	81
5.9.2.5	Middle East & Africa	81
5.10	PATENT ANALYSIS	82
5.10.1	PATENT PUBLICATION TREND	82
5.10.2	JURISDICTION AND TOP APPLICANT ANALYSIS	83
5.10.3	INNOVATIONS AND PATENT REGISTRATIONS	83
5.11	PRICING ANALYSIS	84
5.11.1	INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024	84
5.11.2	INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY REGION, 2022-2024	85
5.12	KEY CONFERENCES & EVENTS, 2025-2026	86
5.13	ECOSYSTEM ANALYSIS	87
5.13.1	ROLE IN ECOSYSTEM	88
5.14	REIMBURSEMENT ANALYSIS	88
5.15	UNMET NEEDS	89
5.16	IMPACT OF AI/GEN AI ON VETERINARY BIOLOGICS MARKET	90
5.16.1	POTENTIAL OF AI IN VETERINARY BIOLOGICS	90
5.16.2	AI USE CASES	90
5.16.3	KEY COMPANIES IMPLEMENTING AI	91
5.17	INVESTMENT & FUNDING SCENARIO	92
5.18	PIPELINE ANALYSIS	92
5.19	IMPACT OF 2025 US TARIFF ON VETERINARY BIOLOGICS MARKET	94
5.19.1	INTRODUCTION	94
5.19.2	KEY TARIFF RATES	95
5.19.3	PRICE IMPACT ANALYSIS	95
5.19.4	IMPACT ON COUNTRY/REGION	96
5.19.5	IMPACT ON END-USE INDUSTRIES	96
5.19.5.1	Veterinary hospitals & clinics	96
5.19.5.2	Veterinary diagnostic labs	96
5.19.5.3	Other end users	96
6	VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE	97
6.1	INTRODUCTION	98
6.2	MONOCLONAL ANTIBODIES	98
6.2.1	INCREASED PET OWNERSHIP AND HUMANIZATION TO RAISE HEALTH AWARENESS AND SPENDING ON ANTIBODY THERAPIES	98
6.3	IMMUNOGLOBULINS & ANTITOXINS	100
6.3.1	INCREASED PREVALENCE OF ZONOTIC AND TOXIN-MEDIATED DISEASES TO FUEL MARKET GROWTH	100
6.4	IMMUNOMODULATORS & IMMUNOSTIMULANTS	102
6.4.1	IMMUNOMODULATORS & IMMUNOSTIMULANTS TO CORRECT IMMUNE DYSFUNCTIONS AND CONTROL OVERACTIVE IMMUNE CONDITIONS	102
6.5	DIAGNOSTIC KITS	103
6.5.1	DIAGNOSTIC KITS TO IMPROVE DISEASE SURVEILLANCE AND MANAGEMENT IN COMPANION ANIMALS, LIVESTOCK, AND POULTRY	103

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7	VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE	106
7.1	INTRODUCTION	107
7.2	COMPANION ANIMALS	107
7.2.1	CANINE	109
7.2.1.1	Widespread ownership of pet dogs to generate consistent demand for preventive care and advanced biologics	109
7.2.2	FELINE	111
7.2.2.1	Rising pet cat population and increasing feline diseases to propel market growth	111
7.3	LIVESTOCK ANIMALS	113
7.3.1	BOVINE	115
7.3.1.1	Need for better herd healthcare and introduction of antibody-based biologics to fuel segment growth	115
7.3.2	SMALL RUMINANT	117
7.3.2.1	Increasing global demand for sheep & goat meat and expanding herd size to boost market growth	117
7.3.3	PORCINE	119
7.3.3.1	Innovation in monoclonal antibodies for infectious diseases to drive market	119
7.3.4	POULTRY	121
7.3.4.1	Rising frequency of poultry diseases to augment market growth for better poultry health and improved food security	121
7.3.5	EQUINE	123
7.3.5.1	Equestrian sports, recreational riding, and managing failure of passive transfer (FPT) in foals to drive market	123
8	VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION	125
8.1	INTRODUCTION	126
8.2	INJECTABLE ROUTE OF ADMINISTRATION	126
8.2.1	SUBCUTANEOUS ROUTE OF ADMINISTRATION	128
8.2.1.1	Ease of administration, reduced pain, and lower risk of tissue damage to aid market growth	128
8.2.2	INTRAMUSCULAR ROUTE OF ADMINISTRATION	130
8.2.2.1	Better immune response and lower rate of injection-site reactions to fuel market growth	130
8.2.3	INTRAVENOUS ROUTE OF ADMINISTRATION	131
8.2.3.1	Rapid action and targeted therapy to drive adoption of intravenous biologics	131
8.2.4	OTHER INJECTABLE ROUTES OF ADMINISTRATION	133
8.3	ORAL ROUTE OF ADMINISTRATION	134
8.3.1	EASE OF ADMINISTRATION AND COST-EFFECTIVENESS TO FOCUS ON LARGE-SCALE, NON-INVASIVE ORAL DELIVERY	134
8.4	OTHER ROUTES OF ADMINISTRATION	136
9	VETERINARY BIOLOGICS MARKET, BY APPLICATION	138
9.1	INTRODUCTION	139
9.2	DERMATOLOGY	139
9.2.1	PREVALENCE OF CHRONIC SKIN CONDITIONS TO AUGMENT VETERINARY DERMATOLOGY MARKET GROWTH	139
9.3	DIAGNOSTIC TESTING	141
9.3.1	RIISING PREVALENCE OF ZOO NOTIC AND VIRAL DISEASES TO INCREASE DEMAND FOR BIOLOGIC-BASED DIAGNOSTIC TOOLS	141
9.4	PAIN MANAGEMENT	142
9.4.1	NEED FOR NON-OPIOID, SIDE-EFFECT-FREE PAIN SOLUTIONS AMONG PET OWNERS TO DRIVE MARKET	142
9.5	INFECTIOUS DISEASE PREVENTION	144
9.5.1	RIISING INCIDENCE OF ZOO NOTIC DISEASES AND ACUTE INFECTIONS TO ACCELERATE USE OF VETERINARY BIOLOGICS	144
9.6	ONCOLOGY	145
9.6.1	FOCUS ON IMMUNE-TARGETED CONTROL OF AGGRESSIVE CANCEROUS TUMORS TO AID MARKET GROWTH	145
9.7	OTHER APPLICATIONS	146
?		
10	VETERINARY BIOLOGICS MARKET, BY END USER	148

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1	INTRODUCTION	149
10.2	VETERINARY HOSPITALS & CLINICS	149
10.2.1	INCREASE IN VETERINARY SPECIALISTS AND RISE IN PET OWNERSHIP TO PROPEL MARKET GROWTH	149
10.3	VETERINARY DIAGNOSTIC LABS	150
10.3.1	VETERINARY DIAGNOSTIC LABS TO BECOME ESSENTIAL IN DISEASE DETECTION WITH PREVENTIVE BIOLOGIC INTERVENTIONS	150
10.4	OTHER END USERS	152
11	VETERINARY BIOLOGICS MARKET, BY REGION	154
11.1	INTRODUCTION	155
11.2	NORTH AMERICA	156
11.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	156
11.2.2	US	159
11.2.2.1	US to dominate North American veterinary biologics market during forecast period	159
11.2.3	CANADA	162
11.2.3.1	Ongoing developments in veterinary monoclonal antibodies and increasing animal health expenditure to fuel market growth	162
11.3	EUROPE	165
11.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	165
11.3.2	GERMANY	168
11.3.2.1	Established veterinary infrastructure and innovation funding to provide favorable environment for biologics adoption	168
11.3.3	UK	170
11.3.3.1	Strong regulatory framework and high pet population to boost market growth	170
11.3.4	FRANCE	173
11.3.4.1	Increase in companion animal health spending by pet owners to propel market growth	173
11.3.5	ITALY	175
11.3.5.1	Better availability of pet products through large-scale outlets to augment market growth	175
11.3.6	SPAIN	178
11.3.6.1	Increased pet population and favorable government regulations to drive market	178
11.3.7	NETHERLANDS	180
11.3.7.1	Focus on meat export to positively influence veterinary biologics market	180
11.3.8	REST OF EUROPE	182
11.4	ASIA PACIFIC	184
11.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	185
11.4.2	JAPAN	187
11.4.2.1	Growing consumption of animal-derived products to propel market growth	187
11.4.3	CHINA	190
11.4.3.1	Large pool of food-producing animals and high companion animal ownership to propel market growth	190
11.4.4	INDIA	193
11.4.4.1	Rising demand for dairy products to fuel market growth	193
11.4.5	AUSTRALIA	196
11.4.5.1	Rise in pet ownership to support increased spending on veterinary care	196
11.4.6	SOUTH KOREA	198
11.4.6.1	Expanding pet care industry and increasing chronic veterinary diseases to drive market	198
11.4.7	NEW ZEALAND	201
11.4.7.1	Increased pet ownership and demand for advanced veterinary treatments to drive market	201
11.4.8	REST OF ASIA PACIFIC	203
11.5	LATIN AMERICA	205

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 206
- 11.5.2 BRAZIL 208
 - 11.5.2.1 Large-scale livestock operations and strong veterinary infrastructure to drive market 208
- 11.5.3 MEXICO 211
 - 11.5.3.1 Increasing demand for targeted biologics in livestock and pets to drive market growth 211
- 11.5.4 REST OF LATIN AMERICA 213
- 11.6 MIDDLE EAST & AFRICA 215
 - 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 215
 - 11.6.2 GCC COUNTRIES 218
 - 11.6.2.1 Kingdom of Saudi Arabia (KSA) 220
 - 11.6.2.1.1 Technology advancements in veterinary diagnostics to boost demand 220
 - 11.6.2.2 United Arab Emirates (UAE) 223
 - 11.6.2.2.1 Favorable government support to drive market 223
 - 11.6.2.3 Rest of GCC Countries 225
 - 11.6.3 REST OF MIDDLE EAST & AFRICA 227
 - 12 COMPETITIVE LANDSCAPE 230
 - 12.1 INTRODUCTION 230
 - 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 230
 - 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY BIOLOGICS MARKET 230
 - 12.3 REVENUE ANALYSIS, 2022-2024 231
 - 12.4 MARKET SHARE ANALYSIS, 2024 232
 - 12.4.1 VETERINARY BIOLOGICS MARKET SHARE ANALYSIS 232
 - 12.4.2 US: VETERINARY BIOLOGICS MARKET SHARE ANALYSIS, 2024 233
 - 12.4.3 VETERINARY DIAGNOSTICS KITS MARKET SHARE ANALYSIS 235
 - 12.4.4 US: VETERINARY DIAGNOSTIC KITS MARKET SHARE ANALYSIS, 2024 236
 - 12.5 RANKING OF KEY PLAYERS 238
 - 12.5.1 VETERINARY BIOLOGICS MARKET RANKING 238
 - 12.5.2 VETERINARY DIAGNOSTIC KITS MARKET RANKING 239
 - 12.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 239
 - 12.6.1 STARS 239
 - 12.6.2 EMERGING LEADERS 239
 - 12.6.3 PERVASIVE PLAYERS 239
 - 12.6.4 PARTICIPANTS 239
 - 12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 241
 - 12.6.5.1 Company footprint 241
 - 12.6.5.2 Region footprint 242
 - 12.6.5.3 Product type footprint 243
 - 12.6.5.4 Animal type footprint 244
 - 12.6.5.5 Application footprint 245
 - 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 246
 - 12.7.1 PROGRESSIVE COMPANIES 246
 - 12.7.2 RESPONSIVE COMPANIES 246
 - 12.7.3 DYNAMIC COMPANIES 246
 - 12.7.4 STARTING BLOCKS 246
 - 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 248
 - 12.7.5.1 Detailed list of key startup/SMEs 248
 - 12.7.5.2 Competitive benchmarking of key startups/SMEs 249

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.8	BRAND/PRODUCT COMPARISON	250
12.9	COMPANY VALUATION & FINANCIAL METRICS	251
12.9.1	FINANCIAL METRICS	251
12.9.2	COMPANY VALUATION	251
12.10	COMPETITIVE SCENARIO	252
12.10.1	PRODUCT LAUNCHES & APPROVALS	252
12.10.2	DEALS	253
12.10.3	EXPANSIONS	254
12.10.4	OTHER DEVELOPMENTS	255
13	COMPANY PROFILES	256
13.1	KEY PLAYERS	256
13.1.1	ZOETIS SERVICES LLC	256
13.1.1.1	Business overview	256
13.1.1.2	Products offered	257
13.1.1.3	Recent developments	259
13.1.1.3.1	Product launches & approvals	259
13.1.1.3.2	Deals	260
13.1.1.3.3	Expansions	260
13.1.1.3.4	Other developments	261
13.1.1.4	MnM view	261
13.1.1.4.1	Right to win	261
13.1.1.4.2	Strategic choices	261
13.1.1.4.3	Weaknesses & competitive threats	261
13.1.2	IDEXX	262
13.1.2.1	Business overview	262
13.1.2.2	Products offered	263
13.1.2.3	Recent developments	267
13.1.2.3.1	Product launches	267
13.1.2.4	MnM view	267
13.1.2.4.1	Right to win	267
13.1.2.4.2	Strategic choices	268
13.1.2.4.3	Weaknesses & competitive threats	268
13.1.3	ELANCO	269
13.1.3.1	Business overview	269
13.1.3.2	Products offered	270
13.1.3.3	Recent developments	271
13.1.3.3.1	Product launches	271
13.1.3.3.2	Deals	271
13.1.3.3.3	Expansions	272
13.1.3.4	MnM view	272
13.1.3.4.1	Right to win	272
13.1.3.4.2	Strategic choices	272
13.1.3.4.3	Weaknesses & competitive threats	272
13.1.4	MERCK & CO., INC.	273
13.1.4.1	Business overview	273
13.1.4.2	Products offered	274
13.1.4.3	Recent developments	275

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.4.3.1 Product launches 275
- 13.1.4.3.2 Expansions 275
- 13.1.4.4 MnM view 275
- 13.1.4.4.1 Right to win 275
- 13.1.4.4.2 Strategic choices 276
- 13.1.4.4.3 Weaknesses & competitive threats 276
- 13.1.5 THERMO FISHER SCIENTIFIC INC. 277
- 13.1.5.1 Business overview 277
- 13.1.5.2 Products offered 278
- 13.1.5.3 MnM view 279
- 13.1.5.3.1 Right to win 279
- 13.1.5.3.2 Strategic choices 279
- 13.1.5.3.3 Weaknesses & competitive threats 279
- 13.1.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 280
- 13.1.6.1 Business overview 280
- 13.1.6.2 Products offered 281
- 13.1.6.3 Recent developments 282
- 13.1.6.3.1 Deals 282
- 13.1.6.3.2 Expansions 282
- 13.1.7 NEOGEN CORPORATION 283
- 13.1.7.1 Business overview 283
- 13.1.7.2 Products offered 284
- 13.1.7.3 Recent developments 285
- 13.1.7.3.1 Deals 285
- 13.1.8 BIO-RAD LABORATORIES, INC. 286
- 13.1.8.1 Business overview 286
- 13.1.8.2 Products offered 287
- 13.1.9 IMMUCELL CORPORATION 288
- 13.1.9.1 Business overview 288
- 13.1.9.2 Products offered 289
- 13.1.9.3 Recent developments 290
- 13.1.9.3.1 Other developments 290
- 13.1.10 INNOVATIVE DIAGNOSTICS 291
- 13.1.10.1 Business overview 291
- 13.1.10.2 Products offered 291
- 13.2 OTHER PLAYERS 295
- 13.2.1 BIONOTE USA INC. 295
- 13.2.2 BIOCHEK 296
- 13.2.3 PLASVACC USA 297
- 13.2.4 NOVAVIVE INC. 298
- 13.2.5 MG BIOLOGICS 299
- 13.2.6 STALLERGENES GREER 300
- 13.2.7 BIOSTONE ANIMAL HEALTH 301
- 13.2.8 COLORADO SERUM COMPANY 302
- 13.2.9 PADULA SERUMS PTY LTD. 303
- 13.2.10 LAKE IMMUNOGENICS 304
- 13.2.11 INBIOS INTERNATIONAL, INC. 304

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.2.12 PRINCETON BIOMEDITECH CORPORATION 305
- 13.2.13 TETRACORE, INC. 306
- 13.2.14 VMRD, INC. 307
- 13.2.15 ANIMAB 308
- ?
- 14 APPENDIX 309
- 14.1 DISCUSSION GUIDE 309
- 14.2 KNOWLEDGESTORE: MARKET SAND MARKETS' SUBSCRIPTION PORTAL 312
- 14.3 AVAILABLE CUSTOMIZATIONS 314
- 14.3.1 GEOGRAPHIC ANALYSIS 314
- 14.3.2 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 314
- 14.3.3 COMPANY INFORMATION 314
- 14.3.4 PRODUCT ANALYSIS 314
- 14.3.5 COUNTRY-LEVEL VOLUME ANALYSIS 314
- 14.3.6 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 314
- 14.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 314
- 14.4 RELATED REPORTS 315
- 14.5 AUTHOR DETAILS 316

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030

Market Report | 2025-10-30 | 317 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-16

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com